Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06151717
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-11-22
Brief Title:
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
PRAGMMATIC A Comparative Clinical Trial to Determine the BEST Initial Therapy for Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma
Detailed Description:
PRIMARY OBJECTIVE
I Compare the overall survival between bortezomib lenalidomide and dexamethasone VRd daratumumab lenalidomide and dexamethasone DRd and daratumumab bortezomib lenalidomide and dexamethasone DVRd used as initial therapy for patients with newly diagnosed MM
OUTLINE This is an observational study
Patients have their medical records reviewed on study
I Compare the overall survival between bortezomib lenalidomide and dexamethasone VRd daratumumab lenalidomide and dexamethasone DRd and daratumumab bortezomib lenalidomide and dexamethasone DVRd used as initial therapy for patients with newly diagnosed MM
OUTLINE This is an observational study
Patients have their medical records reviewed on study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 23-006335 | OTHER | Mayo Clinic Institutional Review Board | None |
| NCI-2023-09520 | REGISTRY | None | None |
| MC230811 | OTHER | None | None |
| PRAGMMATIC | OTHER | None | None |